bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
bluebird bio (BLUE) PT Lowered to $19 at Morgan Stanley
August 11, 2021 8:26 AM EDTMorgan Stanley analyst Matthew Harrison lowered the price target on bluebird bio (NASDAQ: BLUE) to $19.00 (from $35.00) while maintaining a Equalweight rating.
... MoreGoldman Sachs Downgrades bluebird bio (BLUE) to Neutral
August 10, 2021 6:56 AM EDTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Buy to Neutral with a price target of $23.00 (from $63.00).
The analyst comments "We downgrade BLUE from Buy to Neutral and lower our 12-month PT to $23 from $63. First, we note the newly announced clinical hold for gene therapy Lenti-D in cerebral adrenoleukodystrophy (CALD) due to a Suspected Unexpected Serious Adverse... More
bluebird bio (BLUE) PT Lowered to $18 at Stifel
August 9, 2021 1:56 PM EDTStifel analyst Benjamin J. Burnett lowered the price target on bluebird bio (NASDAQ: BLUE) to $18.00 (from $31.00) while maintaining a Hold rating.
The analyst commented, "We remain Hold rated on BLUE following two negative updates: (1) a patient treated with Lenti-D (Cerebral Adrenoleukodystrophy) developed... More
bluebird bio (BLUE) Misses Q2 EPS by 39c
August 9, 2021 7:12 AM EDTbluebird bio (NASDAQ: BLUE) reported Q2 EPS of ($3.58), $0.39 worse than the analyst estimate of ($3.19). Revenue for the quarter came in at $7.47 million versus the consensus estimate of $19.68 million.
For earnings history and earnings-related data on bluebird bio (BLUE) click here.
... More